Compare Fidelity National Information Servcs Inc (FIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs BIO-TECHNE Corp — how do they compare? Fidelity National Information Servcs Inc trades at $34.49 (market cap $17.44B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.2%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and BIO-TECHNE Corp for 63 Days on average.
| FIS | TECH | |
|---|---|---|
Market Cap | $17.44B | $11.37B |
Volume | 6,437,765 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $68.57 | $72.61 |
52-Week Low | $32.44 | $43.31 |
Typical Hold Time | 88 Days | 63 Days |
Enterprise Value | $37.95B | $11.40B |
Dividend Yield | 5.2% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal and neutral oscillators. The stock shows attractive valuation with a P/E of 5.2 and P/S of 1.44, supported by a 27.65% net income margin and 22.33% ROE. Recent earnings beat expectations in Q1 and Q2 2026, and the company secured multiple core banking client wins, enhancing growth prospects.
Outlook is positive given low valuations and earnings momentum, but risks include high debt levels and inconsistent cash flow. Analyst consensus is bullish with a $47.54 price target, implying significant upside. Investors should monitor execution on revenue growth and debt management.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
